@article{40645a7b5290401baa7facf214eb6cc3,
title = "Cost-effectiveness of universal childhood hepatitis A vaccination in Chile",
abstract = "Hepatitis A is an important public health problem in Chile. Childhood vaccination has reduced hepatitis A rates in several countries, prompting this evaluation of its cost-effectiveness in Chile. Using a Markov model, we project mass vaccination would reduce hepatitis A cases among birth cohort members and their personal contacts >80%. Vaccination costs of US$ 5.3-6.4 million would be offset by US$ 9.2-9.4 million reductions in disease costs. Further, approximately 70 fatal infections would be averted and >4600 quality-adjusted life years would be saved. This analysis supports the cost-effectiveness of universal childhood hepatitis A vaccination in Chile.",
keywords = "Cost and cost analysis, Hepatitis A, Vaccination",
author = "Valenzuela, {M. Teresa} and Jacobs, {R. Jake} and Oscar Arteaga and Navarrete, {Maria S.} and Meyerhoff, {Allen S.} and Innis, {Bruce L.}",
note = "Funding Information: We thank the following groups and individuals: the Ministry of Health, for supporting our access to data required to conduct this analysis; Dr. Betsy Hunter and Lorena Calabr{\'a}n, Hospital Luis Calvo Mackenna, for providing information on children with acute liver failure; the Infectious Disease Hospital, Hospital Lucio C{\'o}{\'o}rdoba, for assisting the cost analysis of adult patients; and CVD-Chile, for assisting the cost analysis of pediatric patients. This study was supported in part by an research grant from GlaxoSmithKline Biologicals to Capitol Outcomes Research Inc. Drs. Navarrete and Innis are employees of GlaxoSmithKline.",
year = "2005",
month = jul,
day = "14",
doi = "10.1016/j.vaccine.2005.03.021",
language = "English",
volume = "23",
pages = "4110--4119",
journal = "Vaccine",
issn = "0264-410X",
publisher = "Elsevier BV",
number = "32",
}
